





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/371,612	08/10/1999	ERWIN HACKER	514413-3768	9453
20999 7:	590 08/27/2002			
	LAWRENCE & HAU	EXAMINER		
745 FIFTH AV NEW YORK, 1	'ENUE- 10TH FL. NY 10151		CLA	DY, S
			ART UNIT	PAPER NUMBER
			1616	19
			DATE MAILED: 08/27/2002	. 10

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No. 09/371,612

Applicant(s)

Examiner

Art Unit

1616

Hacker et al

S. Mark Clardy

	The MAILING DATE of this communication appears	on the cover sheet with the correspondence address
	for Reply	
	ORTENED STATUTORY PERIOD FOR REPLY IS SET	TO EXPIRE3 MONTH(S) FROM
	MAILING DATE OF THIS COMMUNICATION. sions of time may be available under the provisions of 37 CFR 1.136 (a). In	no event, however, may a reply be timely filed after SIX (6) MONTHS from the
mailing	g date of this communication. period for reply specified above is less than thirty (30) days, a reply within th	
- If NO	period for reply is specified above, the maximum statutory period will apply a	nd will expire SIX (6) MONTHS from the mailing date of this communication.
- Any re	o to reply within the set or extended period for reply will, by statute, cause the sply received by the Office later than three months after the mailing date of t	**
earned Status	d patent term adjustment. See 37 CFR 1.704(b).	
1) 🔯	Responsive to communication(s) filed on Jun 20, 2	
2a) 💢	This action is <b>FINAL</b> . 2b) ☐ This act	
3) 🗆	Since this application is in condition for allowance e	except for formal matters, prosecution as to the merits is
<b>U</b>	closed in accordance with the practice under Ex par	
Disposi	tion of Claims	
4) 💢	Claim(s) <u>14-22</u>	is/are pending in the application.
4	4a) Of the above, claim(s) <u>16</u>	is/are withdrawn from consideration.
5) 🗆	Claim(s)	is/are allowed.
6) 💢	Claim(s) 14, 15, and 17-22	is/are rejected.
7) 🗆	Claim(s)	is/are objected to.
8) 🗆	Claims	are subject to restriction and/or election requirement.
Applica	ation Papers	
9) 🗆	The specification is objected to by the Examiner.	
10)□	The drawing(s) filed on is/are	a) accepted or b) objected to by the Examiner.
	Applicant may not request that any objection to the d	
11)□		is: a) approved b) disapproved by the Examiner.
	If approved, corrected drawings are required in reply t	
12)	The oath or declaration is objected to by the Exami	ner.
Priority	under 35 U.S.C. §§ 119 and 120	
13)💢	Acknowledgement is made of a claim for foreign pro-	riority under 35 U.S.C. § 119(a)-(d) or (f).
a) [	☑ All b)☐ Some* c)☐ None of:	
	1. $\[ igwedge $ Certified copies of the priority documents hav	e been received.
	2. $\square$ Certified copies of the priority documents hav	e been received in Application No
	3. Copies of the certified copies of the priority de application from the International Bure	ocuments have been received in this National Stage au (PCT Rule 17.2(a)).
*S	ee the attached detailed Office action for a list of the	e certified copies not received.
14)	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. § 119(e).
a) [	$\square$ The translation of the foreign language provisiona	l application has been received.
15)	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. §§ 120 and/or 121.
Attachm		
	otice of References Cited (PTO-892)	4) Interview Summery (PTO-413) Paper No(s).
	otice of Draftsperson's Patent Drawing Review (PTO-948)  formation Disclosure Statement(s) (PTO-1449) Paper No(s).	5) Notice of Informal Patent Application (PTO-152)
ai [1] im	romation disclosure statement(s) (FTO-1445) raper no(s).	6)

Application/Control Number: 09/371,612 Page 2

Art Unit: 1616

Claims 14-22 are pending in this application. The original claims have been canceled; the new claims entered in Amendment B filed June 20, 2002, delete the elected and previously examined species in which the second (B) herbicide is chloransulam.

Applicants' new claims are drawn to compositions and methods of using herbicidal compositions comprising:

- A) a broad spectrum herbicide (glufosinate, glyphosate, imidazolinones, protoporphyrinogen oxidase (PPO) inhibitors)
- B) a second herbicide (groups B0<sup>1</sup> B5; B2 may not be chloransulam)

  In Paper No. 9, applicant elected with traverse of the species comprising:
  - A1.2 glufosinate-ammonium<sup>2</sup> and
  - B2.12 cloransulam-methyl<sup>3</sup>.

Examination has been expanded beyond the originally elected B component. In the discussion below, the parenthetical identifiers (A#.#) or (B#.#) refer to applicants' herbicide designations, e.g., glufosinate (A1.2). Claims 16 has been held withdrawn as being drawn to a non-elected species (A is glyphosate).

The rejection under 35 USC 101 is withdrawn in response to applicants' amendment B

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

<sup>&</sup>lt;sup>1</sup>Note that the group B0 may be any herbicide which is structurally different from those listed in group (A).

<sup>&</sup>lt;sup>2</sup>Ammonium 2-amino-4-(hydroxymethylphosphinyl)butanoate

 $<sup>^3 \ 3-</sup>chloro-2-[[(5-ethoxy-7-fluoro[1,2,4]triazolo[1,5c]pyrimidin-2-yl)sulfonyl] amino] benzoic \ acid$ 

Application/Control Number: 09/371,612

Art Unit:

1616

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Page 3

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 14, 15, and 17-22 are rejected under 35 U.S.C. 102(a) and (b) as being anticipated by Johnson et al<sup>4</sup>. Johnson et al, again, disclose sequential application of glufosinate (glf) with other herbicides in glufosinate tolerant soybean. In addition to the previously examined cloransulam, the additional herbicides may be pendimethalin (B1.4), imazethapyr (A3.2), sulfentrazone (A4.4), flumioxazin (B1.15), sethoxydim (B3.1), or flumiclorac (B2.7).

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 14, 15, and 17-22 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combined teachings of Johnson et al, Agbaje et al (US 6,165,939), Novartis AG (WO 98/09525), Harvey et al<sup>5</sup>, and Steckel et al<sup>6</sup>.

Johnson et al has been discussed above and discloses the utility of sequential application of glufosinate and a second herbicidal agent in glufosinate tolerant soybean.



<sup>&</sup>lt;sup>4</sup>Johnson et al. CROPU Abstract 1998-88956 of "Weed control programs in glufosinate-tolerant soybean" Res. Rep. North Cent. Weed Sci. Soc. (54,234-35). 1997.

<sup>&</sup>lt;sup>5</sup>Harvey, et al. CROPU Abstract 1996-90386, of "Soybean herbicide studies", Res. Rep. North Cent. Weed Sci. Soc. 52, 316-20. 1995.

<sup>&</sup>lt;sup>6</sup>Steckel et al. CROPU Abstract 1996-90678 of "Weed control in glufosinate tolerant soybeans" Res. Rep. North Cent. Weed Sci. Soc. (52, 336-38). 1995.

Page 4

Art Unit: 1616

Agbaje et al, again, teach compositions comprising glufosinate in combination with various secondary chloroacetamide and triazine herbicides, which may be further combined with additional herbicides (col 9, line 38 through col 10, line 35).

Novartis, again, teaches the utility of phospho-herbicides such as glufosinate and glyphosate in synergistic combination with additional herbicidal agents for the control of weeds in phosphoherbicide resistant crops (p. 1). Specifically disclosed secondary herbicides are (abstract): prosulfuron, primisulfuron, dicamba, pyridate, dimethenamide (B1.7), metolachlor (B1.5), fluometuron, propaquizafop (B4.5), atrazine, clodinafop, norflurazon (B1.13), ametryn, terbutylazine, simazine, prometryn, and four additional agents (NOA-402989 and compounds I-III).

Harvey et al, again, teach herbicides in various combined and sequential treatments for soybean crops.

Steckel et al, again, teach glufosinate, among other herbicides, applied alone or in various combinations for the control of weeds in glufosinate tolerant soybeans.

Again, one of ordinary skill in the art would be motivated to combine these references because each discloses a variety of herbicides which may be used in combination with others for weed control in soybeans, especially glufosinate resistant soybeans.

Thus, again, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to have used applicants' elected glufosinate and cloransularn together or in sequence for the control of weeds in glufosinate resistant soybean because the prior art teaches that it was well known to control weeds in glufosinate tolerant crops by application of glufosinate and additional secondary herbicides. One of ordinary skill in the art would have the requisite skill

Application/Control Number: 09/371,612 Page 5

Art Unit:

1616

to select appropriate secondary herbicides based upon the known herbicidal spectrum of activity of the second herbicide to enhance the herbicidal utility of the combination.

Again, the data presented in the specification does not demonstrate unexpected results because it cannot be determined if the differences between the expected and observed results are statistically significant (Table 5: 95% vs 93% control; Table 7: 85% vs 80% control).

No unobvious or unexpected results are noted; no claim is allowed.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103© and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to S. Mark Clardy whose telephone number is (703) 308-4550.

S. Mark Clardy
Primary Examiner

AU 1616